PMID- 23645847 OWN - NLM STAT- MEDLINE DCOM- 20140207 LR - 20211021 IS - 1537-6591 (Electronic) IS - 1058-4838 (Linking) VI - 57 IP - 4 DP - 2013 Aug TI - Skewing of the CD4(+) T-cell pool toward monofunctional antigen-specific responses in patients with immune reconstitution inflammatory syndrome in The Gambia. PG - 594-603 LID - 10.1093/cid/cit285 [doi] AB - BACKGROUND: A common complication of starting antiretroviral therapy (ART) for human immunodeficiency virus (HIV) is the development of immune reconstitution inflammatory syndrome (IRIS) in approximately 25% of patients. Despite similarities with paradoxical reactions to tuberculosis and reversal reactions in leprosy, the exact mechanisms, and therefore potential determinants, of IRIS are still unknown. METHODS: In this longitudinal cohort study, we analyzed 20 patients who developed IRIS following initiation of ART and 16 patients who did not, matched for ART time point. Peripheral blood mononuclear cells were stimulated overnight with a positive control antigen and 2 tuberculosis-specific antigens (purified protein derivative [PPD] and ESAT-6/CFP10), followed by polychromatic flow cytometry for analysis of cytokine production from CD4(+) and CD8(+) T cells. RESULTS: Responses to PPD were significantly higher in IRIS patients compared to controls during the IRIS time point, but CD4(+) and CD8(+) T-cell responses to the positive control stimulation were significantly lower in IRIS patients at all time points. Furthermore, whereas control patients had rejuvenated polyfunctional T-cell responses by 3 months after ART, IRIS patients were strikingly monofunctional (generally interferon gamma alone), even up to 6 months of ART in response to all stimulations. CONCLUSIONS: Our findings suggest that the peripheral T-cell responses to the underlying pathogen are exaggerated in IRIS patients but that the overall quality of the peripheral T-cell pool is significantly reduced compared to non-IRIS patients. Furthermore, these effects are apparent at least up to 3 months after cessation of IRIS. FAU - Wilson, Harry AU - Wilson H AD - Vaccinology Theme, Medical Research Council Unit, Fajara, The Gambia. FAU - de Jong, Bouke C AU - de Jong BC FAU - Peterson, Kevin AU - Peterson K FAU - Jaye, Assan AU - Jaye A FAU - Kampmann, Beate AU - Kampmann B FAU - Ota, Martin O C AU - Ota MO FAU - Sutherland, Jayne S AU - Sutherland JS LA - eng GR - MC_U190071468/MRC_/Medical Research Council/United Kingdom GR - MC_U190085855/MRC_/Medical Research Council/United Kingdom GR - MC_UP_A900_1122/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130503 PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 RN - 0 (Anti-Retroviral Agents) RN - 0 (Antigens, Bacterial) RN - 0 (Bacterial Proteins) RN - 0 (Cytokines) RN - 0 (ESAT-6 protein, Mycobacterium tuberculosis) RN - 0 (Tuberculin) SB - IM MH - Adult MH - Anti-Retroviral Agents/adverse effects/*therapeutic use MH - Antigens, Bacterial/immunology MH - Bacterial Proteins/immunology MH - CD4-Positive T-Lymphocytes/*immunology MH - CD8-Positive T-Lymphocytes/immunology MH - Cohort Studies MH - Cytokines/biosynthesis MH - Female MH - Flow Cytometry MH - Gambia MH - HIV Infections/complications/*drug therapy/immunology MH - Humans MH - Immune Reconstitution Inflammatory Syndrome/*immunology MH - Leukocytes, Mononuclear MH - Longitudinal Studies MH - Male MH - T-Lymphocyte Subsets/*immunology MH - Tuberculin/immunology MH - Tuberculosis/*immunology OTO - NOTNLM OT - HIV OT - West Africa OT - immune reconstitution inflammatory syndrome OT - polyfunctional T cells OT - tuberculosis EDAT- 2013/05/07 06:00 MHDA- 2014/02/08 06:00 CRDT- 2013/05/07 06:00 PHST- 2013/05/07 06:00 [entrez] PHST- 2013/05/07 06:00 [pubmed] PHST- 2014/02/08 06:00 [medline] AID - cit285 [pii] AID - 10.1093/cid/cit285 [doi] PST - ppublish SO - Clin Infect Dis. 2013 Aug;57(4):594-603. doi: 10.1093/cid/cit285. Epub 2013 May 3.